Want to take quizzes and track your credits?
Can a multifaceted pharmacist intervention prevent hospital readmissions and emergency department visits?
In a randomized clinical trial of 1467 Danish participants receiving at least 5 medications, a statistically significant reduced rate of readmissions within 30 and 180 days after inclusion was observed in patients randomized to receive an extended pharmacist intervention compared with those who received usual care or a basic pharmacist intervention.
The proposed multifaceted pharmacist intervention can reduce the number of hospital readmissions and emergency department visits.
Hospital readmissions are common among patients receiving multiple medications, with considerable costs to the patients and society.
To determine whether a multifaceted pharmacist intervention based on medication review, patient interview, and follow-up can reduce the number of readmissions and emergency department (ED) visits.
Design, Setting, and Participants
This randomized clinical multicenter study (Odense Pharmacist Trial Investigating Medication Interventions at Sector Transfer [OPTIMIST]) enrolled patients from September 1, 2013, through April 23, 2015, with a follow-up of 6 months completed on October 31, 2015. Consecutive medical patients in an acute admission ward who were 18 years or older and who used 5 or more medications were invited to participate. Of 1873 patients invited to participate, 1499 (80.0%) accepted. The medication review and patient interview were conducted in the hospital and followed up in collaboration with primary care. Analysis was based on intention to treat.
The patients were randomized into 3 groups receiving usual care (no intervention), a basic intervention (medication review), and an extended intervention (medication review, 3 motivational interviews, and follow-up with the primary care physician, pharmacy, and nursing home).
Main Outcomes and Measures
The prespecified primary outcomes were readmission within 30 or 180 days and ED visits within 180 days. The primary composite end point was readmission or an ED visit within 180 days. Secondary outcomes were drug-related readmissions within 30 and 180 days after inclusion, and all-cause mortality and drug-related mortality.
A total of 1467 patients (679 men [46.3%] and 788 women [53.7%]; median age, 72 years; interquartile range, 63-80 years) were part of the primary analysis, including 498 randomized to usual care, 493 randomized to the basic intervention, and 476 randomized to the extended intervention. The extended intervention had a significant effect on the numbers of patients who were readmitted within 30 days (hazard ratio [HR], 0.62; 95% CI, 0.46-0.84) or within 180 days (HR, 0.75; 95% CI, 0.62-0.90) after inclusion and on the number of patients who experienced the primary composite end point (HR, 0.77; 95% CI, 0.64-0.93). The study showed a nonsignificant reduction in drug-related readmissions within 30 days (HR, 0.65; 95% CI, 0.39-1.09) and within 180 days (HR, 0.80; 95% CI, 0.59-1.08) after inclusion and in deaths (HR, 0.83; 95% CI, 0.22-3.11). The number needed to treat to achieve the primary composite outcome for the extended intervention (vs usual care) was 12.
Conclusions and Relevance
A multifaceted clinical pharmacist intervention may reduce the number of ED visits and hospital readmissions.
clinicaltrials.gov Identifier: NCT03079375
Sign in to take quiz and track your certificates
JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC
Accepted for Publication: December 2, 2017.
Corresponding Author: Lene Vestergaard Ravn-Nielsen, MSc(Pharm), Hospital Pharmacy of Funen, Clinical Pharmacy Department, Odense University Hospital, Solfaldsvej 38, DK-5000 Odense C, Denmark (firstname.lastname@example.org).
Published Online: January 29, 2018. doi:10.1001/jamainternmed.2017.8274
Author Contributions: Ms Ravn-Nielsen had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Ravn-Nielsen, Eriksen, Buck, Hansen, Hallas.
Acquisition, analysis, or interpretation of data: Ravn-Nielsen, Duckert, Lund, Henriksen, Nielsen, Eriksen, Pottegård, Hansen, Hallas.
Drafting of the manuscript: Ravn-Nielsen, Duckert, Nielsen, Pottegård, Hallas.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: Pottegård.
Obtained funding: Ravn-Nielsen, Buck, Hallas.
Administrative, technical, or material support: Duckert, Henriksen, Nielsen, Buck, Hansen, Hallas.
Study supervision: Lund, Pottegård, Hansen, Hallas.
Conflict of Interest Disclosures: Ms Ravn-Nielsen reported receiving grants from the Hospitals Pharmacies’ and Amgros’ Research Development Foundation, 2 public regional foundations, and the Actavis Foundation during the conduct of the study. Dr Hansen reported receiving grants from Menarini and Pfizer unrelated to this project and personally receiving fees from the Danish Association of Pharmaceutical Manufacturers. Dr Hallas reported participating in research projects funded by Novartis, Pfizer, Menarini, MSD, Nycomed, Leo Pharmaceuticals, Astellas, and Alk-Abelló with grants paid to the institution where he was employed and personally receiving fees from the Danish Association of Pharmaceutical Manufacturers, Pfizer, and Menarini unrelated to this project. No other disclosures were reported.
Funding/Support: This study was supported by unrestricted grants from The Hospitals Pharmacies’ and Amgros’ Research Development Foundation, public regional research foundations for Southern Denmark and Zealand, and the Actavis Foundation.
Role of the Funder/Sponsor: The funding organizations had no role in design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: Lisbeth Muurholm, MSc(Pharm), Hospital Pharmacy of Funen, Odense, Denmark, ensured the organizational base for this study. We thank the intervention pharmacists from Odense University Hospital, Odense and Svendborg; the personnel involved from the Hospital Pharmacy of Funen; the clinical pharmacists from Viborg Regional Hospital, Viborg, Denmark, and Holbæk Hospital, Holbæk, Denmark; and all the participating wards, patients, physicians, nurses, general practitioners, nursing homes, and pharmacy personnel from primary care and the impartial clinical pharmacologist.
You currently have no searches saved.